|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
DE69603615T2
(de)
*
|
1995-10-10 |
2000-02-17 |
Pfizer Inc., New York |
Nk-1 rezeptor antagonisten in neurogener entzündung in gen-therapie
|
|
US20030219863A1
(en)
*
|
1997-01-31 |
2003-11-27 |
Bristol-Myers Squibb Company |
Soluble CTLA4 mutant molecules and uses thereof
|
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
|
JP2004517806A
(ja)
*
|
2000-07-03 |
2004-06-17 |
ブリストル−マイヤーズ スクイブ カンパニー |
可溶性ｃｔｌａ４分子を使用するリウマチ疾患の処置方法
|
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
|
PL375139A1
(en)
*
|
2001-01-26 |
2005-11-28 |
Emory University |
Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
|
|
JP4837880B2
(ja)
|
2001-05-23 |
2011-12-14 |
ブリストル−マイヤーズ スクイブ カンパニー |
可溶性ｃｔｌａ４突然変異体分子を使って同種異系島移植片を保護する方法
|
|
US20030086903A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
Therapeutic regimen for treating cancer
|
|
US20060093612A1
(en)
*
|
2002-05-02 |
2006-05-04 |
Srivastava Pramod K |
Use of heat shock proteins to enhance efficacy of antibody therapeutics
|
|
EP1687032B1
(en)
*
|
2003-11-14 |
2010-02-24 |
Genvec, Inc. |
Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc).
|
|
EP2007795B1
(en)
|
2006-03-30 |
2016-11-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Aav capsid proteins
|
|
SI2068918T2
(sl)
|
2006-09-26 |
2024-10-30 |
Access To Advanced Health Institute |
Sestavek za cepljenje, ki vsebuje sintetična pomagala
|
|
US20090181078A1
(en)
*
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
|
EP2612868B1
(en)
*
|
2007-11-01 |
2018-08-15 |
Astellas Pharma Inc. |
Immunosuppressive polypeptides and nucleic acids
|
|
PT2437753T
(pt)
|
2009-06-05 |
2016-11-23 |
Infectious Disease Res Inst |
Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
|
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
|
WO2012042480A1
(en)
|
2010-09-28 |
2012-04-05 |
Kahr Medical Ltd. |
Compositions and methods for treatment of hematological malignancies
|
|
US9044420B2
(en)
|
2011-04-08 |
2015-06-02 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
WO2013119856A1
(en)
|
2012-02-07 |
2013-08-15 |
Infectious Disease Research Institute |
Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
|
|
NZ701881A
(en)
|
2012-05-16 |
2016-10-28 |
Immune Design Corp |
Vaccines for hsv-2
|
|
EP2986303B1
(en)
|
2013-04-18 |
2020-02-26 |
Immune Design Corp. |
Gla monotherapy for use in cancer treatment
|
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
|
RU2761870C2
(ru)
|
2016-05-16 |
2021-12-13 |
Инфекшес Дизис Рисёрч Инститьют |
Состав, содержащий агонист tlr, и способы применения
|
|
CN120189506A
(zh)
|
2016-06-01 |
2025-06-24 |
高级健康研究所 |
含上胶剂的纳米明矾颗粒
|
|
KR102755593B1
(ko)
|
2017-09-08 |
2025-01-20 |
액세스 투 어드밴스드 헬스 인스티튜트 |
사포닌을 포함하는 리포솜 제형 및 사용 방법
|